Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



 
Deep Track Capital, LP
 
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:01/30/2026
 
Deep Track Biotechnology Master Fund, Ltd.
 
Signature:/s/ David Kroin
Name/Title:David Kroin, Director
Date:01/30/2026
 
David Kroin
 
Signature:/s/ David Kroin
Name/Title:David Kroin
Date:01/30/2026
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Ordinary Shares as of January 30, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 192,329,222 shares outstanding as of December 31, 2025, as disclosed by Inventiva S.A. on its website in accordance with article 223-16 of the general regulations of the AMF (French Financial Markets Authority). The beneficially owned shares include 8,504,604 Ordinary Shares, 3,164,379 American Depository Shares ("ADS"), and 9,999,999 Warrants exercisable at an exercise price of 1.50 EUR, subject to the occurrence of a T3 Triggering Event, and subject to the Reporting Persons' beneficial ownership of 4.99% (the "Maximum Percentage") of the outstanding Ordinary Shares. The T3 Triggering event is subject to the release by the Company of topline data announcing that any key primary endpoint or key secondary endpoint of NATiV3 (resolution of NASH without worsening fibrosis and improvement of liver fibrosis without worsening NASH), with any dosage regimen tested in the trial, have been met no later than June 15, 2027. The exercise of the Warrants must take place no later than July 30, 2027. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP Number 46124U107 has been assigned to the ADS of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IVA". Each ADS represents 1 Ordinary Share. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: January 30, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin